142 related articles for article (PubMed ID: 31840546)
21. Clinicopathological factors affecting the prognosis of massive hemorrhage after radiotherapy for patients having nasopharyngeal carcinoma.
Huang Y; Yan D; Wang M; Chen S; Yang F
J Cancer Res Ther; 2021 Nov; 17(5):1219-1224. PubMed ID: 34850770
[TBL] [Abstract][Full Text] [Related]
22. Salvage treatment using carbon ion radiation in patients with locoregionally recurrent nasopharyngeal carcinoma: Initial results.
Hu J; Bao C; Gao J; Guan X; Hu W; Yang J; Hu C; Kong L; Lu JJ
Cancer; 2018 Jun; 124(11):2427-2437. PubMed ID: 29579324
[TBL] [Abstract][Full Text] [Related]
23. [Induction chemotherapy with docetaxel plus cisplatin (TP regimen) followed by concurrent chemoradiotherapy with TP regimen versus cisplatin in treating locally advanced nasopharyngeal carcinoma].
Xie FY; Zou GR; Hu WH; Qi SN; Peng M; Li JS
Ai Zheng; 2009 Mar; 28(3):279-85. PubMed ID: 19619443
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers.
Yang XL; Wang Y; Liang SB; He SS; Chen DM; Chen HY; Lu LX; Chen Y
BMC Cancer; 2018 May; 18(1):606. PubMed ID: 29843648
[TBL] [Abstract][Full Text] [Related]
25. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.
Kong L; Zhang Y; Hu C; Guo Y; Lu JJ
Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641
[TBL] [Abstract][Full Text] [Related]
26. The effects of recombinant human granulocyte colony-stimulating factor mouthwash on radiotherapy-induced oral mucositis in locally advanced nasopharyngeal carcinoma patients.
Liang G; Du W; Ke Q; Huang B; Yang J
Adv Clin Exp Med; 2017; 26(3):409-413. PubMed ID: 28791814
[TBL] [Abstract][Full Text] [Related]
27. Prognosis of nasopharyngeal carcinoma with insufficient radical dose to the primary site in the intensity-modulated radiotherapy era.
Lu T; Xie X; Guo Q; Zhan S; Lin C; Lin S; Zhang Y; Zong J; Pan J
Head Neck; 2019 Oct; 41(10):3516-3524. PubMed ID: 31313419
[TBL] [Abstract][Full Text] [Related]
28. Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control study.
Li Y; Chen QY; Tang LQ; Liu LT; Guo SS; Guo L; Mo HY; Chen MY; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Shao JY; Sun Y; Tan J; Chen S; Ma J; Zhao C; Mai HQ
BMC Cancer; 2017 Aug; 17(1):567. PubMed ID: 28836950
[TBL] [Abstract][Full Text] [Related]
29. Scheduling radiotherapy for patients with nasopharyngeal carcinoma in the corresponding time window can reduce radiation-induced oral mucositis: A randomized, prospective study.
Lv J; Liao S; Li B; Pan L; Wang R
Cancer Med; 2023 Aug; 12(15):16032-16040. PubMed ID: 37537945
[TBL] [Abstract][Full Text] [Related]
30. A new staging system for nasopharyngeal carcinoma based on intensity-modulated radiation therapy: results of a prospective multicentric clinical study.
Kang M; Long J; Li G; Yan H; Feng G; Liu M; Zhu J; Wang R
Oncotarget; 2016 Mar; 7(12):15252-61. PubMed ID: 26918446
[TBL] [Abstract][Full Text] [Related]
31. Effect of Prolonged Radiotherapy Treatment Time on Survival Outcomes after Intensity-Modulated Radiation Therapy in Nasopharyngeal Carcinoma.
Li PJ; Jin T; Luo DH; Shen T; Mai DM; Hu WH; Mo HY
PLoS One; 2015; 10(10):e0141332. PubMed ID: 26506559
[TBL] [Abstract][Full Text] [Related]
32. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study.
Su Z; Mao YP; Tang J; Lan XW; OuYang PY; Xie FY
Tumour Biol; 2016 Apr; 37(4):4429-38. PubMed ID: 26499947
[TBL] [Abstract][Full Text] [Related]
33. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial.
Yang H; Chen X; Lin S; Rong J; Yang M; Wen Q; Shang C; He L; Ren P; Xu S; Zhang J; Liu Q; Pang H; Shi X; Fan J; Sun X; Ma D; Tan B; Zhang T; Zhang L; Hu D; Du X; Zhang Y; Wen S; Zhang X; Wu J
Radiother Oncol; 2018 Jan; 126(1):37-42. PubMed ID: 28864073
[TBL] [Abstract][Full Text] [Related]
34. Implication of comorbidity on the initiation of chemotherapy and survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma.
Guo R; Mao YP; Chen L; Tang LL; Zhou GQ; Liu LZ; Tian L; Zeng MS; Jia WH; Shao JY; Lin AH; Ma J
Oncotarget; 2017 Feb; 8(6):10594-10601. PubMed ID: 27070084
[TBL] [Abstract][Full Text] [Related]
35. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
[TBL] [Abstract][Full Text] [Related]
36. Whole-field simultaneous integrated-boost intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma.
Wong FC; Ng AW; Lee VH; Lui CM; Yuen KK; Sze WK; Leung TW; Tung SY
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):138-45. PubMed ID: 19646824
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the efficacy of the anti-ulcer oral mucosal protective agent RADoralex® in the prevention and treatment of radiation-induced oral mucosal reactions induced during treatment of nasopharyngeal carcinoma.
Yin J; Xie J; Lin J; Weng C; Lu S; Xu P; Zhang S; Luo C; Huang Y; Li L; Lang J; Feng M
Cancer Biol Ther; 2022 Dec; 23(1):27-33. PubMed ID: 34989325
[TBL] [Abstract][Full Text] [Related]
38. Effect of interrupted time during intensity modulated radiation therapy on survival outcomes in patients with nasopharyngeal cancer.
Xu GZ; Li L; Zhu XD
Oncotarget; 2017 Jun; 8(23):37817-37825. PubMed ID: 27911864
[TBL] [Abstract][Full Text] [Related]
39. A retrospective study of the prognostic value of MRI-derived residual tumors at the end of intensity-modulated radiotherapy in 358 patients with locally-advanced nasopharyngeal carcinoma.
He Y; Zhou Q; Shen L; Zhao Y; Lei M; Wei R; Shen L; Cao S
Radiat Oncol; 2015 Apr; 10():89. PubMed ID: 25881159
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy regimens containing taxanes or fluorouracil in nasopharyngeal carcinoma: Which better?
Mi JL; Zhang B; Pan YF; Su YX; Fan JF; Liao SF; Qin XL; Yao DC; Tang HY; Jiang W
Oral Oncol; 2017 Nov; 74():34-39. PubMed ID: 29103749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
